work and deaths related to occupational illnesses. A dece dent is classified as Hispanic if documentation is available indicating that the decedent was of Mexican, Puerto Rican, Cuban, or Central or South American descent, or of other Spanish culture or origin, regardless of race. Deaths of undocumented workers are included. In this report, cer tain data are presented only for the period [2003] [2004] [2005] [2006] because, in 2003, industry coding changed to the 2002 North American Industry Classification System. Death rates were calculated for workers aged >16 years, using estimates of employed civilian workers from the BLS Current Popu lation Survey (CPS) (2) . CPS is a monthly survey of ap proximately 60,000 households that uses a combination of in-person and telephone interviews with a single person reporting for all household members. Undocumented per sons are included in CPS.
Work-related injury deaths among Hispanic workers dur ing 1992-2006 totaled 11,303 (Figure 1 ), approximately 13% of all U.S. work-related injury deaths during that period. Median age of Hispanic decedents was 35 years, compared with a median age of 42 years for all workers. Approximately 95% of Hispanic decedents were male. The annual work-related injury death rate for Hispanic workers exceeded the rate for all U.S. workers every year during 1992-2006, with the exception of 1995. In 2006, the work-related injury death rate for Hispanic workers was (Table) , an increase from 52% in 1992. Approximately 70% of these decedents were born in Mexico. During 2003 During -2006 , the most common industries employing Hispanics who died from work-related injuries were construction (34%), administrative and waste services (11%), agriculture/forestry/fishing/hunting (10%), and transportation/warehousing (10%). Of those states with 30 or more work-related injury deaths among Hispanics during [2003] [2004] [2005] [2006] , the highest numbers of fatalities were in California (773 deaths), Texas (687), and Florida (417); however, the highest fatality rates were in South Carolina (22.8 per 100,000 Hispanic workers), Oklahoma (10.3), Georgia (9.6), and Tennessee (8.9) (Table) .
Editorial Note: Although work-related injury death rates declined generally and among Hispanics in the United States from 1992 to 2006, disparities between Hispanics and all workers persisted, with Hispanics consistently experienc ing higher rates. In 2006, rates for Hispanics and all work ers were above the Healthy People 2010 target for work-related injury deaths of 3.2 deaths per 100,000 work ers (objective 20-1) (4). Foreign-born Hispanic workers were at especially high risk, and a large proportion of deaths occurred in the construction industry. Much of the increased risk for Hispanic workers likely can be attributed to hold ing high-risk jobs (5) . However, an analysis of Hispanic work-related injury deaths in the construction industry found that Hispanic workers also had elevated rates when compared with non-Hispanic workers in the same occupa tions (e.g., laborers or roofers) (6) .
In-depth investigations of approximately 200 deaths of Hispanic workers by CDC's National Institute for Occu pational Safety and Health and state public health and labor agencies during 1992-2006 suggested characteris tics that contributed to higher numbers of work-related injury deaths among Hispanic workers, including inad equate knowledge and control of recognized safety hazards and inadequate training and supervision of workers, often The findings in this report are subject to at least five limitations. First, the number of deaths of Hispanic work ers might be undercounted in the CFOI database (6) , resulting in an underestimate of the death rate among His panics. Second, Hispanic ethnicity might have been misclassified in CFOI, which relies on secondary data sources, and also in CPS, which uses a single reporter for all house hold members. Third, the number of Hispanic workers might be undercounted in the CPS, which relies on stable residences for sequential interviews and largely collects data via telephone. An undercount of the total population of Hispanic workers would result in overestimate of Hispanic work-related injury death rates (6) . Fourth, Hispanic work ers are a heterogeneous population, and analyses that aggregate deaths for all Hispanics might mask differences among subpopulations. Finally, the data do not address potential contributors to Hispanic worker risk associated with cultural and social norms or economic status. For example, Hispanic workers, especially those who are for eign born, might be more willing to perform tasks with higher risk and more hesitant to decline such tasks for fear of losing their jobs.
CDC, the Occupational Safety and Health Administra tion (OSHA), and other agencies have provided additional Spanish-language occupational health and safety materials and training opportunities for employers, supervisors, and workers (7, 8) . OSHA has worked with employers to publi cize best practices for Hispanic worker education and train ing programs (8) . In addition, federally supported research projects are exploring grassroots approaches to improving occupational health and safety among Hispanic and other immigrant workers.** Others agencies can build upon these ¶ Individual case reports of Hispanic worker deaths are available at http:// www2a.cdc.gov/NIOSH-FACE/state.asp?Category=0009&Category2= ALL&Submit=Submit. ** Additional information available at http://www.dph.sf.ca.us/phes/ work_unidos.htm.
projects to develop culturally competent programs that engage Hispanic workers in identifying and addressing their occupational health and safety concerns.
occurred after direct exposure to a health-care worker (HCW) with pertussis. This report describes the outbreak investigation and highlights the importance of following recommendations to administer tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine to HCWs to prevent transmission of pertussis to patients. Immediately after identification of the six infants with pertussis at children's hospital A, hospital staff members reviewed newborn nursery charts at general hospital A. One staff member (HCW A) was identified as having directly cared for all six infants during their stay in the newborn nursery. Review of work logs for all shifts identified four additional hospital workers who had been present while the six infants were in the newborn nursery.
From early to mid-June until July 17, while working in the newborn nursery at general hospital A, HCW A had exhibited symptoms of pertussis, including cough, posttussive emesis, and dyspnea. Her spouse reportedly had similar symptoms after he returned from a trip to Califor nia, 2-3 weeks before HCW A began exhibiting her symp toms. HCW A, aged 24 years, had been fully vaccinated for pertussis during early childhood. HCW A and a nurs ery coworker with cough symptoms were tested for pertus sis by PCR; only HCW A tested positive. On July 17, HCW A was furloughed from general hospital A for 5 days and treated with erythromycin. Her husband also was prescribed erythromycin.
After obtaining Institutional Review Board approval from the institutions involved, staff members at children's hos pital A reviewed the charts and laboratory records of all patients aged <4 months who had received a diagnosis of pertussis during June-August 2004. During that period, no additional cases of pertussis were reported to the county health department from facilities other than children's hospital A. A case of pertussis was defined in accordance with the Council of State and Territorial Epidemiologists (CSTE) case definition for pertussis, with one variation. The CSTE case definition for pertussis is a cough illness lasting at least 2 weeks with one of the following symp toms and no other apparent cause (as reported by a health professional): paroxysms of coughing, inspiratory "whoop," or posttussive vomiting. Confirmatory criteria consist of either isolation of B. pertussis from a clinical specimen or positive PCR assay for B. pertussis. For this investigation, that definition was modified to include infants with cough illness of any duration so that the definition might cover cases in newborns in the first 2 weeks of life. PCR amplifi cation and detection of a 114 nucleotide segment of the B. pertussis IS481 sequence (1) was conducted using nucleic acid extracted from nasopharyngeal swabs.
The review of laboratory records and charts at children's hospital A revealed that 29 infants aged <4 months met the case definition for pertussis during June-August. Of these 29 infants, 11 (including the six previously known patients) had been born at general hospital A and directly exposed to HCW A in the newborn nursery. All 11 had been treated at children's hospital A with erythromycin and recovered; none developed hypertrophic pyloric stenosis, which has been reported as a complication of treatment of infants with erythromycin (2) . Five of the infants required admission to the pediatric intensive-care unit (PICU), and four were treated in the general pediatric medical unit; one infant was treated in the emergency department, and one was treated as an outpatient (Table) . Median age of the 11 infants born at general hospital A was 31 days at the time of pertussis diagnosis, compared with a median age of 61 days for the other 18 infants with diagnosed pertussis, who were born at 12 other general hospitals during June-August.
On July 21, 2004, the county health department directed general hospital A to contact the families of all infants who had been in its newborn nursery during May 31-July 17 so that the infants could be screened for respi ratory symptoms and administered antibiotics as needed. Families of 158 infants who had been in the newborn nurs ery during May 31-July 17 were contacted, and a total of 110 infants returned to general hospital A. Eighteen of the 110 had cough but were PCR negative; they received eryth romycin prophylaxis. Two infants had cough and also were PCR positive; they were treated for pertussis, and one was admitted to children's hospital A. In addition, three family members reported cough or runny nose but were PCR nega tive; they were treated with erythromycin.
During the period that HCW A exhibited symptoms, she directly cared for 113 infants, 11 of whom subsequently had a diagnosis of pertussis, resulting in an attack rate of 9.7%. One other possible case was identified in a sibling aged 3 years. Interviews with families when they brought their infants back to general hospital A for screening, revealed no other exposures to pertussis. No secondary cases of pertussis among HCWs at either general hospital A or children's hospital A were discovered. After HCW A was furloughed and treated, no new cases of pertussis were iden tified during September-October 2004 in infants born at general hospital A.
Editorial Note: Pertussis is a highly contagious, vaccinepreventable illness caused by Bordetella pertussis infection. Complications of pertussis (e.g., seizures, pneumonia, encephalopathy, and cardiovascular compromise) can occur, especially in infants aged <1 year. Deaths from pertussis occur most frequently among infants; the case-fatality rate is 1.8% for newborns and infants aged <2 months (3) . From 1980 From -1989 From to 1990 From -1999 , the number of infant deaths from pertussis increased from 61 (1.67 deaths per million) to 93 (2.40 deaths per million) (4). Newborns most commonly acquire pertussis from adults with undi agnosed disease (5) . Reports on outbreaks of pertussis in health-care facilities and neonatal nurseries have been published previously (6, 7) .
In 2004, the reported incidence of pertussis in the United States nearly tripled compared with 2001, and the num ber of reported cases exceeded any year since 1959 (8) . This increase might have resulted, in part, from increased use of more sensitive PCR testing (8) . CDC recommenda tions call for culture confirmation of infection in one or more cases in an outbreak. However, in the outbreak described in this report, no culture confirmation was per formed. The medical staff at children's hospital A requested PCR testing, as did the local health department. Current molecular detection methods for detection of B. pertussis have high sensitivity compared with culture, but occasion ally can be prone to false positives, depending on the target sequences, interpretation of results, and subjects tested (9) . In a recent report describing outbreaks of respiratory ill ness mistakenly attributed to pertussis, PCR was used inappropriately as a mass screening tool on a large number of persons who did not meet the CSTE case definition for pertussis (9) . For the infants described in this report, a high index of suspicion for pertussis was based on clinical symp toms, and PCR testing was used to confirm diagnoses of pertussis. HCW A also met the CTSE case definition for pertussis.
In 2005, Tdap vaccine was licensed by the Food and Drug Administration for use in adolescents and adults. In December 2006, the Advisory Committee on Immuniza tion Practices (ACIP) recommended use of Tdap vaccine for HCWs with direct patient contact and for adults who have or might have close contact with infants aged <12 months (3). This recommendation was based on the docu mented risk for transmission of pertussis in health-care facilities. Despite the costs involved for health-care facili ties, one study suggests the return on investment from vac cinating HCWs with Tdap vaccine is twice the cost of the vaccine (10) .
Widespread implementation of Tdap vaccination of ado lescents and adults as recommended by ACIP can reduce the risk for pertussis in the community and the incidence of pertussis transmission in health-care facilities. This out break also highlights the importance of rapid recognition of pertussis transmission in health-care settings and rapid response from hospital and public health practitioners to identify the source and prevent more extensive spread of disease, particularly among vulnerable newborns and infants. 
Public

Clinical description
An illness characterized by acute or insidious onset of fever, night sweats, undue fatigue, anorexia, weight loss, headache, and arthralgia.
Laboratory criteria for diagnosis
• Isolation of Brucella spp. from a clinical specimen, or • Fourfold or greater rise in Brucella agglutination titer between acute-and convalescent-phase serum speci mens obtained >2 weeks apart and studied at the same laboratory, or • Demonstration by immunofluorescence of Brucella spp. in a clinical specimen.
Case classification
Probable: clinically compatible case that is epidemio logically linked to a confirmed case or that has supportive serology (i.e., Brucella agglutination titer >160 in one or more serum specimens obtained after onset of symptoms).
Confirmed: a clinically compatible illness that is laboratory confirmed. female resident aged 35 years. The woman reported having intermittent fever, chills, sweats, body aches, weakness, headaches, and malaise since October 13, 2004. She was examined first at a local emergency department in Novem ber 2004, diagnosed with acute bronchitis, and discharged without a prescription for antimicrobials. She subsequently was examined by an infectious disease specialist on January 3, 2005, at which time brucellosis was considered based on continued nonspecific symptoms, polyarthritis, and an atypical lymphocytosis seen on a peripheral blood smear. Blood was obtained for culture and Brucella antibody test ing on January 3 and January 24. Blood cultures were nega tive after 10 days. The EIA results from a commercial laboratory were interpreted as positive IgM and negative IgG, consistent with early brucellosis. On the basis of these results, on February 1 the patient was prescribed a twice daily, 6-week course of antimicrobial therapy of doxycy cline (100 mg) and rifampin (300 mg). She stopped tak ing both antimicrobials after a short period because of side effects. After confirmatory testing by BMAT of the January 24 serum sample, performed February 14 at CDC, was negative, no further treatment for brucellosis was recom mended. No other infectious etiologies were identified as a cause of the patient's symptoms, and she was lost to followup.
After the February 1 report, but before receiving the nega tive BMAT results, Nassau County and Florida epidemi ologists began an investigation to identify possible exposures to Brucella species. The patient reported no recent contact with animals or animal fluids. She had eaten goat cheese from several sources while traveling in Michigan during May-July 2004 and while staying at a Georgia youth hos tel in July 2004, 3-5 months before her illness onset. No unpasteurized dairy products were discovered at the iden tified sources that supplied locations where the woman ate. At the youth hostel, all dairy products used for cooking were pasteurized and purchased from local markets; how ever, guests often contributed food they had brought with them, and exact origins of shared foods were difficult to determine. Editorial Note: Brucellosis is a classic bacterial zoonosis. Common Brucella species that are pathogenic in humans and their usual animal reservoirs include B. melitensis in sheep and goats, B. abortus in cattle, and B. suis in swine. B. melitensis, considered the most pathogenic species in humans, has not been reported in animals in the United States since 1999. Symptoms of human brucellosis vary, and include periodic or undulant fever, muscle aches, back pain, and fatigue. Diagnosis can be difficult because bru cellosis has a prolonged and variable incubation period (5 days to 5 months), often presents as a nonspecific febrile syndrome, and occurs in acute, chronic, and asymptom atic forms.
Definitive diagnosis of brucellosis requires isolation and identification of the Brucella species. More commonly, cases are diagnosed serologically by detection of agglutinating antibodies. The reference method is the standard tube agglutination test (SAT), of which BMAT is a modified format (4). Brucella-specific agglutination tests involve direct agglutination of bacterial antigens by specific anti bodies. Agglutination tests detect antibodies of IgM, IgG, and IgA classes. IgM antibodies are predominant in acute infection but decline within weeks, whereas relapses are accompanied by transient elevations of IgG and IgA anti bodies but not IgM (5) .
Evidence of Brucella antibody by nonagglutination-based tests does not meet the current CDC/CSTE case definition for brucellosis (Box). In the context of a clinically compat ible illness, brucellosis is confirmed by a fourfold or greater rise in Brucella agglutination titer between acute-and convalescent-phase serum specimens obtained at least 2 weeks apart, isolation of Brucellae in culture, or demonstra tion of organism presence by specific immunohistochemi cal staining (3) . A clinically compatible case that is epidemiologically linked to a confirmed case or that has supportive serology (i.e., Brucella agglutination titer of >160 in one or more serum specimens obtained after onset of symptoms) is considered a probable case.
The Brucella EIA reagents used in this investigation were obtained from Panbio, Inc. (Columbia, Maryland); they are sold as ASRs in the United States but elsewhere as com plete test kits. ASRs are used as active components of assays developed by individual clinical laboratories (6) . Laboratories that use ASRs are responsible for evaluating and validating their assay and for establishing and main taining assay interpretation and performance criteria, including sensitivity and specificity (6) . Specificity of the Panbio IgM and IgG EIA, based on a study in a brucellosis endemic area, was reported as 100% (7); IgM detection sensitivities using different EIA formats has been reported as 67%-100%, with limited specificity data (8) . Such tests might have different performance characteristics when used in areas with low disease prevalence, such as the United States. The CDC laboratory has observed that specimens that were positive using EIA tests from commercial labora tories often were negative when tested by BMAT. Results of EIA tests must be confirmed by a reference method such as BMAT, which is quantitative and provides evidence of rising antibody titers when paired sera are tested.
Cross-reactions and false-positive test results can occur in Brucella antibody tests. The primary immunodeterminant and virulence factor for Brucella species is the cell wall sur face lipopolysaccharide, which is antigenically similar to the lipopolysaccharide of other gram-negative rods. Falsepositive Brucella antibody test results can be caused by crossreactivity of antibodies to Escherichia coli O157, Francisella tularensis, Moraxella phenylpyruvica, Yersinia enterocolitica, and certain Salmonella species (9) . Most cross-reacting antibodies are IgM (10), making interpretation of any IgM assay difficult because of false positivity. Therefore, results obtained using EIA should be confirmed by a reference method.
This investigation highlights the need to confirm screen ing serologic test results by using established reference test ing methods and to identify the presence of known risk factors before committing a patient to prolonged antimi crobial therapy for brucellosis or initiating public health investigations. Testing of persons with compatible signs and symptoms for brucellosis should be supported by a thor ough history that reveals likely exposure through travel to an area where brucellosis is endemic, consumption of an unpasteurized dairy product, hunting potentially infected wildlife species, or laboratory exposure. Testing of persons in the absence of a suggestive exposure increases the likeli hood of false-positive results and lowers the overall positive predictive value of the assay used. Rapid Brucella antibody assays can be useful as screening tools when results are interpreted in the context of performance characteristics of the particular test; however, CDC recommends that all positive results obtained by rapid serologic assays be con firmed with Brucella-specific agglutination testing. For questions about risk factors or to request confirmatory test ing for brucellosis in patients with strong evidence of expo sure, health-care providers should contact their local or state health department.
Notice to Readers
Cancer Survivorship -June 2008
National Cancer Survivors Day was June 1. Throughout the month of June, CDC is focusing attention on the needs of cancer survivors. Currently, approximately 11 million persons in the United States are living with a previously diagnosed cancer, a threefold increase from the estimated 3 million persons who were living with cancer in 1971 (1, 2) .
Today, approximately 65% of persons diagnosed with cancer are expected to live at least 5 years after diagnosis (2), but disparities in health care can affect survival. Lowincome persons who have inadequate or no health insur ance coverage are more likely to be diagnosed with cancer at later stages, when the potential for survival is reduced (3).
The National Action Plan for Cancer Survivorship (4), developed by CDC, the Lance Armstrong Foundation, and multiple partners, identified public health needs of cancer survivors and proposed strategies to meet those needs. Additional information, including descriptions of CDC's cancer survivorship research initiatives and partnerships and
Notice to Readers
Assessment Tool for Evaluating Emergency and Disaster Shelters
Shelters provide refuge for communities and at-risk popu lations during and after emergencies and disasters. Effec tive emergency response requires that environmental health practitioners rapidly assess the health and safety of the shelter environment for these populations.
To help meet this challenge, CDC and partners have developed an environmental health shelter assessment form (available in English and Spanish) that covers general areas of environmental health, such as food safety, sanitation, and service and companion animal care. It also provides space for listing immediate needs. The form provides guid ance and information that environmental health practitio ners and shelter managers can use with existing plans, procedures, resources, and management systems.
The environmental health shelter assessment tool, includ ing the assessment form, instructions for its use, and train ing materials, is available at http://www.emergency.cdc.gov/ shelterassessment. and the duration of these conditions. Conditions lasting >3 months are classified as chronic; selected conditions (e.g., arthritis, diabetes, cancer, and heart conditions) are considered chronic regardless of duration. † Estimates are age adjusted using the projected 2000 U.S. population as the standard population and using four age groups: 25-44 years, 45-64 years, 65-74 years, and >75 years. Estimates are based on household interviews of a sample of the civilian, noninstitutionalized U.S. population. Persons who did not know whether they had a limitation and those with a limitation who did not know whether the condition causing the limitation was chronic were excluded from the denominators. § General Educational Development.
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S. Atlantic
E.S. Central
W.S. Central
- 0 0 - - - 0 0 - 14 N 0 0 N N C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 1 - 2 - 0 0 - - Puerto Rico -0 4
New England
- 0 1 2 - - 0 1 3 5 - 0 1 2 9 Colorado - 0 1 1 - - 0 2 3 9 - 0 2 6 14 Idaho § - 0 2 - 3 - 0 2 - - - 0 2 2 3 Montana § - 0 2 - 1 - 0 1 - 2 - 0 1 4 1 Nevada § - 0 2 - 6 - 0 3 4 1 - 0 2 6 3 New Mexico § - 0 2 - - - 0 1 - 1 - 0 1 4 1 U t a h - 0 1 - - - 0 3 - 5 - 0 2 2 7 Wyoming § - 0 1 - - - 0 0 - - - 0 1 2 2
Pacific
N 0 0 N N - 0 0 - - - 0 0 - - C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 1 - - - 0 0 - - Puerto Rico N 0 0 N N - 0 1 1 1 - 0 1 2 5 U.S. Virgin Islands N 0 0 N N - 0 0 - - - 0 0 - - C.N.- 0 0 - - N 0 0 N N American Samoa - 0 0 - - N 0 0 N N N 0 0 N N C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 0 - - N 0 0 N N Puerto Rico - 0 0 - - - 10 1 1 - - 0 0 - - - 0 1 1 1 C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 5 5 5 - 0 0 - - - 0N 0 0 N N N 0 0 N N Washington N 0 0 N N N 0 0 N N American Samoa - 0 12 19 4 N 0 0 N N C . N . M . I . - - - - - - - - - - Guam - 0 0 - - - 0 0 - - Puerto Rico N 0 0 N N N 0 0 N N U.S. Virgin Islands - 0 0 - - N 0
